Autolus Therapeutics (AUTL) Cash from Investing Activities (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Cash from Investing Activities for 9 consecutive years, with $86.5 million the latest figure, recorded in Q4 2025.

• Quarterly Cash from Investing Activities rose 122.56% year-over-year to $86.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $158.5 million (up 140.16% YoY) and the FY2025 annual result came in at $158.5 million, up 140.16% from the prior year.
• Cash from Investing Activities climbed to $86.5 million in Q4 2025 per AUTL's latest filing, from $35.5 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for AUTL reached as high as $95.9 million in Q2 2025 and fell as low as -$383.6 million in Q4 2024.
• A 5-year average of -$13.3 million and a median of -$1.5 million in 2021 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 25870.82% — and 2025, when it soared 11504.88%.
• Year by year, Cash from Investing Activities stood at -$1.6 million in 2021, then soared by 60.06% to -$633000.0 in 2022, then slumped by 133.33% to -$1.5 million in 2023, then plunged by 25870.82% to -$383.6 million in 2024, then jumped by 122.56% to $86.5 million in 2025.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $86.5 million, $35.5 million, and $95.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.